AbbVie Inc. (NYSE:ABBV) was the target of some unusual options trading on Wednesday. Investors bought 278 put options on the stock. This represents an increase of 121% compared to the average volume of 126 put options.
A number of research firms recently commented on ABBV. Piper Jaffray Companies reiterated a “buy” rating and issued a $85.00 target price on shares of AbbVie in a research report on Thursday, August 3rd. Barclays PLC reiterated a “hold” rating and issued a $68.00 target price on shares of AbbVie in a research report on Thursday, September 28th. Evercore ISI reiterated an “outperform” rating and issued a $100.00 target price (up from $95.00) on shares of AbbVie in a research report on Saturday, September 30th. BidaskClub upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 11th. Finally, BMO Capital Markets reiterated a “hold” rating and issued a $66.00 target price on shares of AbbVie in a research report on Thursday, September 28th. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $93.68.
In related news, SVP Azita Saleki-Gerhardt sold 8,300 shares of the business’s stock in a transaction dated Monday, September 11th. The stock was sold at an average price of $85.02, for a total value of $705,666.00. Following the sale, the senior vice president now directly owns 93,099 shares in the company, valued at $7,915,276.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael Severino sold 25,633 shares of the business’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $94.69, for a total value of $2,427,188.77. Following the completion of the sale, the executive vice president now owns 114,922 shares in the company, valued at $10,881,964.18. The disclosure for this sale can be found here. Insiders sold 58,932 shares of company stock worth $5,379,432 over the last 90 days. Company insiders own 0.23% of the company’s stock.
A number of large investors have recently made changes to their positions in the stock. Formidable Asset Management LLC grew its stake in AbbVie by 0.3% in the second quarter. Formidable Asset Management LLC now owns 3,926 shares of the company’s stock worth $285,000 after purchasing an additional 10 shares in the last quarter. WealthTrust Axiom LLC grew its stake in AbbVie by 0.3% in the second quarter. WealthTrust Axiom LLC now owns 4,307 shares of the company’s stock worth $312,000 after purchasing an additional 15 shares in the last quarter. Abner Herrman & Brock LLC grew its stake in AbbVie by 0.3% in the second quarter. Abner Herrman & Brock LLC now owns 6,293 shares of the company’s stock worth $456,000 after purchasing an additional 18 shares in the last quarter. Bollard Group LLC grew its stake in AbbVie by 0.5% in the second quarter. Bollard Group LLC now owns 3,764 shares of the company’s stock worth $273,000 after purchasing an additional 19 shares in the last quarter. Finally, St. Louis Trust Co grew its stake in AbbVie by 0.7% in the second quarter. St. Louis Trust Co now owns 3,411 shares of the company’s stock worth $248,000 after purchasing an additional 23 shares in the last quarter. 68.16% of the stock is currently owned by institutional investors.
AbbVie (NYSE:ABBV) opened at $93.61 on Friday. The company has a market capitalization of $150,590.00, a P/E ratio of 17.84, a PEG ratio of 1.31 and a beta of 1.52. AbbVie has a 52 week low of $58.60 and a 52 week high of $98.26. The company has a debt-to-equity ratio of 5.08, a quick ratio of 1.32 and a current ratio of 1.45.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, October 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.39 by $0.02. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company had revenue of $7 billion for the quarter, compared to analysts’ expectations of $7 billion. During the same quarter in the prior year, the firm earned $1.21 earnings per share. AbbVie’s revenue was up 8.8% compared to the same quarter last year. sell-side analysts forecast that AbbVie will post 5.55 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Investors of record on Friday, January 12th will be paid a $0.71 dividend. The ex-dividend date is Thursday, January 11th. This represents a $2.84 annualized dividend and a yield of 3.03%. This is a boost from AbbVie’s previous quarterly dividend of $0.64. AbbVie’s dividend payout ratio is 61.84%.
ILLEGAL ACTIVITY NOTICE: “AbbVie Target of Unusually High Options Trading (ABBV)” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://sportsperspectives.com/2017/11/18/abbvie-target-of-unusually-high-options-trading-abbv.html.
AbbVie Inc (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions.
Receive News & Ratings for AbbVie Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc. and related companies with MarketBeat.com's FREE daily email newsletter.